Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer

Regorafenib is a multikinase inhibitor which showed benefits in pretreated metastatic colorectal cancer patients. Hepatotoxicity has been described as a frequent side effect. We report the case of a 65-year-old patient presenting with jaundice, fever, and hepatocellular insufficiency which led to de...

Full description

Saved in:
Bibliographic Details
Published inCase reports in oncology Vol. 10; no. 2; pp. 790 - 794
Main Authors Béchade, Dominique, Desjardin, Marie, Castain, Claire, Bernard, Pierre-Henri, Fonck, Marianne
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 29.08.2017
Karger Publishers
Subjects
Cancer therapies
Case Report
Case reports
Chemotherapy
Colorectal cancer
Drug dosages
Hepatitis
Inhibitor drugs
Liver
Liver failure
Lymphatic system
Metabolism
Metabolites
Metastasis
Metastatic colorectal cancer
Mutation
Patients
Regorafenib
Targeted cancer therapy
Toxicity
Regorafenib
Liver failure
Metastatic colorectal cancer
Online AccessGet full text

Cover

More Information
Summary:Regorafenib is a multikinase inhibitor which showed benefits in pretreated metastatic colorectal cancer patients. Hepatotoxicity has been described as a frequent side effect. We report the case of a 65-year-old patient presenting with jaundice, fever, and hepatocellular insufficiency which led to death of the patient. She had previously been treated with several lines of chemotherapy for sub- and diaphragmatic ganglionic metastases of a colon adenocarcinoma. There were no liver metastases. The fatal liver failure occurred at the beginning of treatment with regorafenib at a dosage of 3 tablets per day. No concomitant treatment was given, and other causes of liver damage were eliminated. The liver biopsy showed hepatocyte necrosis with lymphocyte infiltration. This observation illustrates the risk of severe hepatic involvement typically occurring within the first 2 months of treatment. Monitoring liver biology every 2 weeks is essential during the first 2 months to detect any hepatotoxicity.
ISSN:1662-6575
1662-6575
DOI:10.1159/000479732